

BioAiAssist Report

Query: **what percent of mgmt methylation in gbm patients benefit from temodar**

Tool hits: 1

Failures: 0

Slots

Genes: MGMT EGFR IDH CD8

Diseases: glioblastoma

Drugs: temodar temozolomide tmz

Highlights

- Top gene: MGMT

Publications (top)

Title	ID	Cutoff %	HR (95% CI)	Median OS (mo)	Median PFS (mo)
Identifying the best treatment choice for relapsing/refractory glioblastoma: a systematic review with multiple Bayesian network meta-analyses.	PMID:39674575		0.5		
Efficacy of vaccination therapy in newly diagnosed and recurrent glioblastoma patients: a meta-analysis.	PMID:40597861				
Modified Target Delineation and Moderately Hypofractionated Radiotherapy for High-Grade Glioma: A Randomized Clinical Trial.	PMID:40705330		4		
Phase 2 trial of personal dendritic cell vaccines in newly diagnosed glioblastoma: 3-year follow-up and correlations with survival.	PMID:40938661				
Analysis of Overall Survival in High-Grade Glioma Patients Treated With Surgery and Adjuvant Therapy.	PMID:40861539		2	15	
Clinical value of the <i>MGMT</i> promoter methylation score in IDHmt low-grade glioma for predicting benefit from temozolomide treatment.	PMID:40041202				
Cisplatin and Alternating Temozolomide in Recurrent High-Grade Gliomas: Efficacy and the Role of Tumor-Infiltrating Lymphocytes in a Phase II Clinical Trial.	PMID:40661859				

Title	ID	Cutoff %	HR (95% CI)	Median OS (mo)	Median PFS (mo)
Biomolecular Predictors of Recurrence Patterns and Survival in IDH-Wild-Type Glioblastoma: A Retrospective Analysis of Patients Treated with Radiotherapy and Temozolomide.	PMID:40722305		0.48		
Efficacy and Safety of Prolonged Adjuvant Temozolomide Treatment in Glioblastoma: Prospective Study of 81 Patients Undergoing up to 101 Cycles of Treatment.	PMID:40426599		18		
Magnetic resonance spectroscopy guided radiotherapy boost for patients with glioblastoma.	PMID:40246915				30
Timing Matters: Overall Treatment Time, Radiotherapy Interruptions, and Outcomes in glioblastomas – Prognostic Significance in Different Biological Sub- Groups	DOI:10.21203/rs.3.rs-7156531/v1		1.41		
Bioinformatic and clinical experimental assay uncovers resistance and susceptibility mechanisms of human glioblastomas to temozolomide and identifies new combined and individual survival biomarkers outperforming <i>MGMT</i> promoter methylation.	PMID:39525666		0.18		
Unlocking glioblastoma: breakthroughs in molecular mechanisms and next-generation therapies.	PMID:40542948				
Oligodendroglioma of the Hippocampus: A Case Report and Systematic Review on Therapeutic Approaches of Oligodendroglioma After WHO 2021 Classification.	PMID:40143126				
Analysis of Patients with Glioblastoma Treated with Standard 6-Week Chemoradiation Followed by Temozolomide: Treatment Outcomes and Prognostic Factors.	PMID:40142187				
Identification of Autophagy-Related Prognostic Signature for Glioblastoma Standard Therapy.	PMID:40592763				
Long-term survival, patterns of progression, and patterns of use for patients with newly diagnosed glioblastoma treated with or without Tumor Treating Fields (TTFields) in a real-world setting.	PMID:40163248				
Peripheral biomarkers predict survival in patients with glioblastoma treated with temozolomide	PMC12046623				

Title	ID	Cutoff %	HR (95% CI)	Median OS (mo)	Median PFS (mo)
Outcomes From a Contemporary Mono-Institutional Cohort of Histone-Mutant Diffuse Hemispheric Glioma: A Rare and Aggressive Pediatric-Type High-Grade Primary Brain Tumor.	PMID:40759477				
Predictive role of MGMT and IDH status in the efficacy of bevacizumab for high-grade glioma: a retrospective study.	PMID:40927528				

Clinical Trials (top)

NCT	Title	Status	Phase	Condition
-----	-------	--------	-------	-----------

Tools Run

Server	Tool	OK	Elapsed (ms)
europmc	search_publications	✓	1381